NZ570413A - Methods for the diagnosis of dementia and other neurological disorders - Google Patents

Methods for the diagnosis of dementia and other neurological disorders

Info

Publication number
NZ570413A
NZ570413A NZ570413A NZ57041307A NZ570413A NZ 570413 A NZ570413 A NZ 570413A NZ 570413 A NZ570413 A NZ 570413A NZ 57041307 A NZ57041307 A NZ 57041307A NZ 570413 A NZ570413 A NZ 570413A
Authority
NZ
New Zealand
Prior art keywords
dementia
metabolite
metabolites
patient
sample
Prior art date
Application number
NZ570413A
Other languages
English (en)
Inventor
Lisa Cook
Dayan Goodenowe
Original Assignee
Phenomenome Discoveries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenomenome Discoveries Inc filed Critical Phenomenome Discoveries Inc
Publication of NZ570413A publication Critical patent/NZ570413A/en

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N37/00—Details not covered by any other group of this subclass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/16—Phosphorus containing
    • Y10T436/163333—Organic [e.g., chemical warfare agents, insecticides, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Electrochemistry (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ570413A 2006-02-28 2007-02-28 Methods for the diagnosis of dementia and other neurological disorders NZ570413A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77729006P 2006-02-28 2006-02-28
US80477906P 2006-06-14 2006-06-14
US88888307P 2007-02-08 2007-02-08
PCT/CA2007/000313 WO2007098585A1 (en) 2006-02-28 2007-02-28 Methods for the diagnosis of dementia and other neurological disorders

Publications (1)

Publication Number Publication Date
NZ570413A true NZ570413A (en) 2011-07-29

Family

ID=38458611

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ570413A NZ570413A (en) 2006-02-28 2007-02-28 Methods for the diagnosis of dementia and other neurological disorders

Country Status (11)

Country Link
US (2) US8304246B2 (enExample)
EP (3) EP1922325B1 (enExample)
JP (3) JP5496513B2 (enExample)
KR (1) KR20080104350A (enExample)
AT (1) ATE535535T1 (enExample)
AU (1) AU2007219666A1 (enExample)
CA (2) CA2689848A1 (enExample)
HK (1) HK1208467A1 (enExample)
IL (1) IL193426A0 (enExample)
NZ (1) NZ570413A (enExample)
WO (1) WO2007098585A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007346587C1 (en) 2007-02-08 2015-01-22 Med-Life Discoveries Lp Methods for the treatment of Senile Dementia of the Alzheimer's Type
CN101675337A (zh) 2007-04-13 2010-03-17 菲诺梅诺米发现公司 用于缩醛磷脂缺乏介导的衰老疾病的诊断和危险评估的方法
AU2008280806B2 (en) * 2007-07-26 2014-12-11 Phenomenome Discoveries Inc. Methods for the diagnosis, risk assessment, and monitoring of autism spectrum disorders
SG10201704689XA (en) 2008-01-18 2017-07-28 Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
US20140365895A1 (en) 2008-05-13 2014-12-11 Apple Inc. Device and method for generating user interfaces from a template
US9121844B1 (en) * 2008-09-09 2015-09-01 Sociedad Europea de Analisis Diferencial de Movilidad Method to analyze and classify persons and organisms based on odor patterns from released vapors
TWI475989B (zh) 2008-12-22 2015-03-11 Phenomenome Discoveries Inc 縮醛磷脂類化合物，含彼之醫藥組成物以及治療老化疾病的方法
SG10201405975VA (en) 2009-10-01 2014-11-27 Phenomenome Discoveries Inc Serum-based biomarkers of pancreatic cancer and uses thereof for diseasedetection and diagnosis
SG10201505723UA (en) 2010-07-23 2015-09-29 Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
MX2013000917A (es) 2010-07-23 2013-07-05 Harvard College Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
CA2806304A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
CN103314291B (zh) * 2010-12-28 2016-05-11 藤野脑研究株式会社 通过血液样品判定痴呆症用的检验方法
CA2812129C (en) * 2011-11-17 2014-10-21 Phenomenome Discoveries Inc. Methods for the synthesis of 13c labeled plasmalogen
WO2013119651A1 (en) * 2012-02-08 2013-08-15 Nestec Sa Methods for diagnosing cognitive impairment
CA2863184A1 (en) * 2012-02-15 2013-08-22 Basf Se Means and methods for assessing neuronal toxicity
CN104246781B (zh) * 2012-03-29 2019-06-14 皇家飞利浦有限公司 用于改进神经科医师的关于阿尔茨海默氏病的工作流程的系统与方法
EA201590024A1 (ru) 2012-06-15 2015-05-29 Гарри Стилли Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток
CN104603289A (zh) 2012-06-15 2015-05-06 哈里·斯泰利 检测疾病或病状的方法
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
WO2014197339A1 (en) 2013-06-08 2014-12-11 Apple Inc. Device, method, and graphical user interface for synchronizing two or more displays
WO2015071145A1 (en) * 2013-11-14 2015-05-21 Nestec S.A. Lipid biomarkers of healthy ageing
US20160235778A1 (en) * 2014-03-13 2016-08-18 Massachusetts Institute Of Technology Compositions containing pufa, uridine and choline and methods of use thereof
EP4428251A3 (en) 2014-09-11 2024-12-18 Immunis.AI, Inc. Methods of detecting prostate cancer
US10006925B2 (en) 2016-05-30 2018-06-26 Universal Diagnostics, S. L. Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps
GB201611596D0 (en) * 2016-07-04 2016-08-17 British American Tobacco Investments Ltd Apparatus and method for classifying a tobacco sample into one of a predefined set of taste categories
WO2018157013A1 (en) * 2017-02-24 2018-08-30 Duke University Compositions and methods related to sex-specific metabolic drivers in alzheimer's disease
EP3684463B1 (en) 2017-09-19 2025-05-14 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11318277B2 (en) 2017-12-31 2022-05-03 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
EP3811245A4 (en) 2018-06-19 2022-03-09 Ellipsis Health, Inc. MENTAL HEALTH ASSESSMENT SYSTEMS AND METHODS
JP7389421B2 (ja) * 2018-07-13 2023-11-30 Ｐｓｔ株式会社 精神・神経系疾患を推定する装置
US11452839B2 (en) 2018-09-14 2022-09-27 Neuroenhancement Lab, LLC System and method of improving sleep
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
WO2022263927A2 (en) * 2021-06-17 2022-12-22 Phoska Biopharma Pte. Ltd. Plasmalogen derivatives and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009371A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Antemortem diagnostic test for alzheimer's disease
US5731354A (en) * 1996-05-06 1998-03-24 Clarion Pharmaceuticals Inc. Treatment for the inhibition of neuro-degenerative disease states
US6177476B1 (en) * 1998-08-27 2001-01-23 Clarion Pharmaceuticals Inc. Nutritional supplements for replenishing plasmalogens
CA2298181C (en) 2000-02-02 2006-09-19 Dayan Burke Goodnough Non-targeted complex sample analysis
WO2001078652A2 (en) 2000-04-14 2001-10-25 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
EP1317765A2 (en) * 2000-09-08 2003-06-11 Oxford GlycoSciences (UK) Limited Automated identification of peptides
CA2446886A1 (en) * 2001-04-06 2002-10-17 Biovision Ag Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
US7202044B2 (en) 2001-05-09 2007-04-10 Biovision Ag Method for detecting a progressive, chronic dementia disease, and corresponding peptides and detection agents
CA2745724C (en) 2002-08-23 2015-06-02 Bayer Schering Pharma Aktiengesellschaft Biomarkers comprising peptide sequence vnhvtlsqpk for diagnosing alzheimer's disease
US7794948B2 (en) 2003-11-07 2010-09-14 Vermilllion, Inc. Biomarkers for alzheimer's disease
WO2005085838A2 (en) * 2004-03-02 2005-09-15 Vanderbilt University Computational analysis of mass spectroscopic lipid data
WO2005116659A2 (en) * 2004-05-18 2005-12-08 Neurodx, Llc Compositions and methods relating to alzheimer’s disease
JP4176749B2 (ja) * 2005-07-29 2008-11-05 学校法人帝京大学 疾病検査法
US8026099B2 (en) * 2007-07-26 2011-09-27 Washington University Lipid profile as a biomarker for early detection of neurological disorders

Also Published As

Publication number Publication date
EP2851369A2 (en) 2015-03-25
US20130110408A1 (en) 2013-05-02
WO2007098585A1 (en) 2007-09-07
HK1113160A1 (en) 2008-09-26
EP1922325B1 (en) 2011-11-30
JP5496513B2 (ja) 2014-05-21
EP2322531A3 (en) 2011-09-07
EP1922325A4 (en) 2009-05-27
US8304246B2 (en) 2012-11-06
EP2851369A3 (en) 2015-06-17
HK1208467A1 (en) 2016-03-04
JP2012255793A (ja) 2012-12-27
US20100003761A1 (en) 2010-01-07
AU2007219666A1 (en) 2007-09-07
JP2009528517A (ja) 2009-08-06
CA2640748A1 (en) 2007-09-07
CA2689848A1 (en) 2007-09-07
EP1922325A1 (en) 2008-05-21
IL193426A0 (en) 2009-05-04
KR20080104350A (ko) 2008-12-02
ATE535535T1 (de) 2011-12-15
EP2322531A2 (en) 2011-05-18
JP2014197018A (ja) 2014-10-16
CA2640748C (en) 2010-04-20

Similar Documents

Publication Publication Date Title
US8304246B2 (en) Methods for the diagnosis of dementia and other neurological disorders
US8026099B2 (en) Lipid profile as a biomarker for early detection of neurological disorders
JP5977795B2 (ja) 多発性硬化症を診断するための生物マーカー、及びその方法
CN112834653B (zh) 用于诊断脑白质病变的生物标志物f3及其应用
CN112798727B (zh) 用于诊断脑白质病变的生物标志物f7及其应用
JP2015231392A (ja) 自閉症の代謝バイオマーカー
Iriondo et al. Isopropanol extraction for cerebrospinal fluid lipidomic profiling analysis
CA2693177A1 (en) Methods for the diagnosis, risk assessment, and monitoring of autism spectrum disorders
Mill et al. Recent advances in understanding of Alzheimer’s disease progression through mass spectrometry-based metabolomics
CN101395163A (zh) 诊断痴呆和其它神经病症的方法
AU2016206360B2 (en) Methods for the diagnosis of dementia and other neurological disorders
HK1154013A (en) Methods for the diagnosis of dementia and other neurological disorders
HK1113160B (en) Methods for the diagnosis of dementia and other neurological disorders
EP4370931B1 (en) Biomarkers for alzheimer's disease
Huang Mass Spectrometry-Based Metabolomics: Platform Development and Application to Neurodegenerative Disease
HK1184435A (en) Biomarkers for diagnosing multiple sclerosis, and methods thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 28 FEB 2017 BY CPA GLOBAL

Effective date: 20140130

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 28 FEB 2020 BY CPA GLOBAL

Effective date: 20140910

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 28 FEB 2027 BY CPA GLOBAL

Effective date: 20140910